Irritable bowel syndrome - PubMed (original) (raw)
Review
Irritable bowel syndrome
N J Talley. Intern Med J. 2006 Nov.
Abstract
Conceptually, the irritable bowel syndrome (IBS) has been considered a brain-gut functional disorder, but this paradigm is under serious challenge. There is increasing evidence that organic disease of the gastrointestinal tract can be identified in subsets of patients who fulfil the Rome criteria for IBS. Evidence for subtle inflammatory bowel disease, serotonin dysregulation, bacterial overgrowth and central dysregulation continue to accumulate. The underlying causes of IBS remain to be adequately identified, but postinfectious IBS is a clear-cut entity. Furthermore, a genetic contribution to IBS also seems likely. Diagnosis continues to be based on the symptom profile and the absence of alarm features. A heightened awareness of coeliac disease masquerading as IBS is becoming accepted. Management remains largely based on symptomatic rather than on disease-modifying therapy, but this is likely to change in the near future. Here, recent advances in the pathophysiology and management of IBS are considered.
Conflict of interest statement
Potential conflicts of interest: Consultant or research support: Novartis, Solvay, Axcan, Bohringer-Ingelheim, Giaconda and GlaxoSmithKline.
Figures
Figure 1
Prevalence of irritable bowel syndrome (IBS) and other major functional gastrointestinal disorders in an Australian population sample based on Rome II criteria. n = 762; ▨ females; □ males.
Similar articles
- Irritable bowel syndrome: a clinical review.
Chey WD, Kurlander J, Eswaran S. Chey WD, et al. JAMA. 2015 Mar 3;313(9):949-58. doi: 10.1001/jama.2015.0954. JAMA. 2015. PMID: 25734736 Review. - The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome.
Grover M, Herfarth H, Drossman DA. Grover M, et al. Clin Gastroenterol Hepatol. 2009 Jan;7(1):48-53. doi: 10.1016/j.cgh.2008.08.032. Epub 2008 Sep 3. Clin Gastroenterol Hepatol. 2009. PMID: 18848909 Review. - Management of irritable bowel syndrome in the elderly.
Kurniawan I, Kolopaking MS. Kurniawan I, et al. Acta Med Indones. 2014 Apr;46(2):138-47. Acta Med Indones. 2014. PMID: 25053688 Review. - Importance of early diagnosis in patients with irritable bowel syndrome.
Halpert AD. Halpert AD. Postgrad Med. 2010 Mar;122(2):102-11. doi: 10.3810/pgm.2010.03.2127. Postgrad Med. 2010. PMID: 20203461 Review. - Diagnostic and therapeutic strategies in the irritable bowel syndrome.
Cremonini F, Talley NJ. Cremonini F, et al. Minerva Med. 2004 Oct;95(5):427-41. Minerva Med. 2004. PMID: 15467518 Review.
Cited by
- Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings.
Coss-Adame E, Rao SS. Coss-Adame E, et al. Curr Gastroenterol Rep. 2014 Apr;16(4):379. doi: 10.1007/s11894-014-0379-z. Curr Gastroenterol Rep. 2014. PMID: 24595616 Free PMC article. Review. - On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study.
Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro-Delestrain MC. Ducrotte P, et al. Int J Clin Pract. 2014 Feb;68(2):245-54. doi: 10.1111/ijcp.12333. Epub 2013 Oct 21. Int J Clin Pract. 2014. PMID: 24147869 Free PMC article. Clinical Trial. - Effect of electro-acupuncture on substance P, its receptor and corticotropin-releasing hormone in rats with irritable bowel syndrome.
Ma XP, Tan LY, Yang Y, Wu HG, Jiang B, Liu HR, Yang L. Ma XP, et al. World J Gastroenterol. 2009 Nov 7;15(41):5211-7. doi: 10.3748/wjg.15.5211. World J Gastroenterol. 2009. PMID: 19891022 Free PMC article. - Clinical impact of a gluten-free diet on health-related quality of life in seven fibromyalgia syndrome patients with associated celiac disease.
Rodrigo L, Blanco I, Bobes J, de Serres FJ. Rodrigo L, et al. BMC Gastroenterol. 2013 Nov 9;13:157. doi: 10.1186/1471-230X-13-157. BMC Gastroenterol. 2013. PMID: 24209578 Free PMC article. - Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multicenter study in Japan.
Yamada E, Tsunoda S, Abe T, Uchida E, Teraoka H, Watanabe S, Kawana I, Tagri M, Hosaka N, Nagai K, Nishino H, Nakajima A. Yamada E, et al. J Gastroenterol. 2017 Mar;52(3):301-307. doi: 10.1007/s00535-016-1215-z. Epub 2016 Apr 29. J Gastroenterol. 2017. PMID: 27129979 Clinical Trial.
References
- Drossman DA, Corrazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG, et al. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates; 2006.
- Drossman DA, Corrazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. McLean, VA: Degnon Associates; 2000.
- Talley N, Spiller RC. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002;360:555–64. - PubMed
- Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol. 2005;100:1174–84. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources